化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性分析

Analysis on Clinical Effect and Safety of Chemotherapy Combined with Aromatase Inhibitor in the Treatment of Patients with Postmenopausal Positive Hormone Receptor Breast Cancer

目的分析化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性。方法选取2020年2月至2022年6月我院收治的90例绝经后激素受体阳性乳腺癌患者,随机分为参照组(45例)和联合组(45例)。参照组予以TE(多西他赛+表柔比星)化疗,联合组在参照组基础上予以阿那曲唑治疗,比较两组患者的客观缓解率(ORR)及不良反应发生率。结果联合组ORR为55.56%,明显高于参照组的33.33%(P<0.05)。联合组治疗期间不良反应发生率为31.11%,与参照组的37.78%比较差异无统计学意义(P>0.05)。结论化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者,可明显提升临床疗效,但未明显增加患者不良反应的发生,安全性较高。

Objective To analyze the clinical effect and safety of chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer.Methods 90 patients with postmenopausal positive hormone receptor breast cancer admitted to our hospital from February 2020 to June 2022 were selected and randomly divided into reference group(45 cases)and combined group(45 cases).The reference group was treated with TE(docetaxel+epirubicin)chemotherapy,and the combined group was treated with anastrozole on the basis of the reference group.The objective response rate(ORR)and the incidence of adverse reactions were compared between the two groups.Results The ORR of the combined group was 55.56%,significantly higher than 33.33%of the reference group(P<0.05).During the treatment,the incidence of adverse reactions in the combined group was 31.11%,which had no statistical difference with 37.78%in the reference group(P>0.05).Conclusions Chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer,can significantly improve the clinical efficacy,but does not significantly increase the incidence of adverse reactions with higher safety.